Parsaclisib

Parsaclisib
Clinical data
ATC code	L01EM05 (WHO) ;
Identifiers
	IUPAC name 4R)-4-[3-[(1S)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one;
CAS Number	1426698-88-5;
PubChem CID	86677874;
DrugBank	DB14867;
ChemSpider	64835232;
UNII	OS7097575K;
KEGG	D11437;
ChEMBL	ChEMBL4297615;
Chemical and physical data
Formula	C20H22ClFN6O2
Molar mass	432.88 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC1=C(C(=C(C=C1[C@H](C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)[C@H]4CC(=O)NC4;
	InChI InChI=InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1; Key:ZQPDJCIXJHUERQ-QWRGUYRKSA-N;

Parsaclisib is an investigational drug that it being evaluated for the treatment of B-cell malignancies. It is a PI3Kδ (phosphoinositide 3-kinase) inhibitor.^[1]^[2]

References

^ Gerds AT, Bartalucci N, Assad A, Yacoub A (August 2022). "Targeting the PI3K pathway in myeloproliferative neoplasms". Expert Review of Anticancer Therapy. 22 (8): 835–843. doi:10.1080/14737140.2022.2093192. PMID 35763287.
^ "Parsaclisib - Incyte Corporation". AdisInsight. Springer Nature Switzerland AG.

Clinical data

ATC code	L01EM05 (WHO)
Identifiers
IUPAC name 4R)-4-[3-[(1S)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one
CAS Number	1426698-88-5
PubChem CID	86677874
DrugBank	DB14867
ChemSpider	64835232
UNII	OS7097575K
KEGG	D11437
ChEMBL	ChEMBL4297615
Chemical and physical data
Formula	C₂₀H₂₂ClFN₆O₂
Molar mass	432.88 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCOC1=C(C(=C(C=C1[C@H](C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)[C@H]4CC(=O)NC4
InChI InChI=InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1 Key:ZQPDJCIXJHUERQ-QWRGUYRKSA-N